NCT04066660

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

Terminated NA Last updated 13 January 2025

What this trial tests

NA trial testing Oligo Fucoidan in Advanced Hepatocellular Carcinoma in 87 participants. Terminated before completion.

Timeline

1 October 2019

Primary endpoint
30 June 2024

31 July 2024

Quick facts

Lead sponsor	Hi-Q Marine Biotech International, Ltd.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	87
Start date	1 October 2019
Primary completion	30 June 2024
Estimated completion	31 July 2024
Sites	1 location across China

Drugs / interventions tested

• Oligo Fucoidan
• Placebo

Conditions studied

• Advanced Hepatocellular Carcinoma — all drugs for Advanced Hepatocellular Carcinoma →

Sponsor

Hi-Q Marine Biotech International, Ltd.

Who can join

18 and older, any sex, with Advanced Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy in patients with advanced hepatocellular carcinoma. The previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease control rate in metastatic colorectal cancer. The previous study might provide insights into the development of cancer treatments, particularly in the combination of natural or herbal products with chemotarget agents.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Extraction and Modification of Macroalgal Polysaccharides for Current and Next-Generation Applications.
   Jönsson M, Allahgholi L, Sardari RRR, Hreggviðsson GO, et al · · 2020 · cited 94× · PMID 32093097 · DOI 10.3390/molecules25040930
2. Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy.
   Zubair H, Khan MA, Anand S, Srivastava SK, et al · · 2022 · cited 44× · PMID 32470379 · DOI 10.1016/j.semcancer.2020.05.009
3. Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy.
   Sansone C, Bruno A, Piscitelli C, Baci D, et al · · 2021 · cited 39× · PMID 33504012 · DOI 10.3390/cells10020231
4. From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.
   Wang E, Sorolla MA, Krishnan PDG, Sorolla A. · · 2020 · cited 31× · PMID 32041255 · DOI 10.3390/biom10020248
5. Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling.
   Wu SY, Yang WY, Cheng CC, Lin KH, et al · · 2020 · cited 24× · PMID 33377648 · DOI 10.1002/ctm2.252
6. Immunopotentiating Activity of Fucoidans and Relevance to Cancer Immunotherapy.
   Li Y, McGowan E, Chen S, Santos J, et al · · 2023 · cited 22× · PMID 36827169 · DOI 10.3390/md21020128
7. Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.
   Godiyal Y, Maheshwari D, Taniguchi H, Zinzuwadia SS, et al · · 2024 · cited 21× · PMID 39690423 · DOI 10.1186/s40779-024-00586-9
8. Ten Years of Research on Fucoidan and Cancer: Focus on Its Antiangiogenic and Antimetastatic Effects.
   Turrini E, Maffei F, Fimognari C. · · 2023 · cited 18× · PMID 37233501 · DOI 10.3390/md21050307